Zacks Investment Research
01 Oct 2025, 14:41 UTC · 50w ago
Verdict
Headline takes no side. We score AKRO +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Akero Therapeutics (AKRO) has returned 70.7% year-to-date, significantly outperforming the Medical sector average of -0.4%.
More positive than 76% of claims this week
The Zacks Consensus Estimate for Akero Therapeutics' full-year earnings has increased by 4.9% over the past quarter.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of claims this week
Humana (HUM) holds a Zacks Rank #2 (Buy) with a 3.8% increase in its consensus EPS estimate over the last three months.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), positive earnings estimate revisions, and has significantly outperformed its sector year-to-date.
More positive than 73% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), increasing EPS estimates, and has outperformed its industry.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2d ago
+15.1%
Price agrees with the score
$54.65 vs $47.48 close before publication (Sep 30) · not market-adjusted
AKRO chart →
